Keywords: evocalcet, cinacalcet, secondary hyperparathyroidism (SHPT), gastrointestinal symptoms, Izumo scale questionnaire 〈Abstract〉 Cinacalcet, a representative calcimimetic compound, can reduce parathyroid hormone levels, but it causes a high incidence of gastrointestinal (GI) tract related adverse events. Evocalcet is a new calcimimetic that is expected to reduce GI symptoms. Using the Izumo scale questionnaire, we analyzed the changes in GI symptoms seen after switching from cinacalcet to evocalcet. Nineteen hemodialysis patients with secondary hyperparathyroidism were included. We prospectively analyzed their GI symptoms at three points: before they switched to evocalcet and at three and six months after they switched to evocalcet. Switching to evocalcet decreased the number of patients suffering from GI symptoms from 14 to 9 after three months and to 12 after six months. In particular, the score for the feeling of fullness significantly decreased from 0.8±1.3 points (mean ±standard deviation) before the switch to 0.7±1.5 points after three months and 0.1±1.9 points after six months (p <0.05, respectively), and that for diarrhea also significantly decreased from 1.1±2.3 points to 0.6±1.6
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.